DAFNA Capital Management’s ADC Therapeutics ADCT Stock Holding History

DAFNA Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.5K	Buy	77,081 +5,000	+7%	+$14.6K	0.02%	88
2026 Q1	$270K	Sell	72,081 -5,000	-6%	-$19.7K	0.06%	80
2025 Q4	$272K	Sell	77,081 -45,000	-37%	-$183K	0.06%	75
2025 Q3	$488K	Hold	122,081	–	–	0.12%	70
2025 Q2	$327K	Sell	122,081 -102,000	-46%	-$215K	0.09%	70
2025 Q1	$316K	Hold	224,081	–	–	0.09%	76
2024 Q4	$446K	Buy	224,081 +20,000	+10%	+$52.3K	0.11%	75
2024 Q3	$643K	Hold	204,081	–	–	0.15%	69
2024 Q2	$645K	Buy	+204,081	New	+$811K	0.15%	70

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DAFNA Capital Management's ADCT Position: Q2 2026 in Review

DAFNA Capital Management increased its ADC Therapeutics (ADCT) stake by 6.9% in Q2 2026, buying an estimated $14.6K and bringing the position to 77,081 shares worth $82.5K. The position accounts for 0.02% of the portfolio, ranked #88.

DAFNA Capital Management first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $645K in Q2 2024. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

DAFNA Capital Management held 77,081 shares of ADC Therapeutics worth $82.5K as of Q2 2026.
DAFNA Capital Management bought 5,000 ADC Therapeutics shares in Q2 2026, an estimated $14.6K.
ADC Therapeutics made up 0.02% of DAFNA Capital Management's portfolio in Q2 2026, its #88 holding.
DAFNA Capital Management first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
DAFNA Capital Management's ADC Therapeutics position peaked at $645K in Q2 2024.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.